“Our team has made great progress this past quarter. Our growing body of encouraging data coupled with the successful completion of our first GMP batch for PALI-2108 has positioned us for some exciting momentum as we prepare for the initiation of our Phase 1 clinical trial. Based on the preclinical data demonstrated to date, we believe PALI-2108 has the potential to be the first approved PDE4 inhibitor for UC and importantly, provide a much-needed solution for patients,” commented J.D. Finley, Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
- Palisade Bio selects dose for upcoming Phase 1 study of PALI-2108
- Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
- Palisade Bio Participates in Virtual Investor “What this Means” Segment
- Palisade Bio completes microbiome study on PALI-2108
Questions or Comments about the article? Write to editor@tipranks.com